Accelerating Vaccine Development with Disposable Technologies

Strategic Insights -

The demand for vaccines is increasing globally, driven by factors such as emerging pandemics and the growing need for cancer treatments. However, the vaccine development process is complex, costly, and time-consuming, with typical development cycles lasting 8 to 12 years and costing between $300 and $800 million USD. To address these challenges, biopharmaceutical companies are seeking innovative solutions to streamline production and reduce costs. Disposable technologies, such as Pall's Mustang membrane capsules, offer a promising approach to accelerate vaccine development by eliminating time-consuming steps, safety risks, and sources of capital and recurring expenses.

Key Takeaways:

  • Disposable technologies can significantly improve process economics by eliminating time-consuming steps, safety risks, and sources of capital and recurring expenses.
  • The cancer vaccine market is predicted to reach $6 billion by 2010, requiring efficient production and flexibility to meet the demand.
  • Pall's Mustang membrane capsules demonstrate higher binding capacity compared to conventional resin- or gel-based column chromatography, making them an ideal choice for large molecule applications.
  • The use of disposable prefilters, sterilizing grade capsules, and final filters provides exponential time, cost, and labor savings in the vaccine development process.
  • Pall's total process management approach is aligned with regulatory requirements, such as cGMP Annex 13, effective May 2004 in Europe.
  • Disposable technologies can reduce the risk of cross-batch contamination and worker exposure to biohazards inherent in vaccine development.

Statistics:

  • Vaccine development cycles typically last 8 to 12 years.
  • The cost of vaccine development ranges from $300 to $800 million USD.
  • The cancer vaccine market is expected to reach $6 billion by 2010.
  • Disposable technologies can provide exponential time, cost, and labor savings in the vaccine development process.
  • Pall's Mustang membrane capsules demonstrate higher binding capacity compared to conventional resin- or gel-based column chromatography.

Sources:

  • Business Wire, "Viral Vaccine Development is a Long and Costly Process Governed by Stringent Regulatory Controls" (April 20, 2005)
  • Pall Corporation, "Total Process Management: Technologies for Speeding Up the Development of Viral and Cancer Vaccines"
  • cGMP Annex 13, effective May 2004 in Europe
  • "Pall Corporation Reports Fiscal 2004 Results" (released on February 2005)